Clinical Trial Corner

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.

A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

The novel drug, IDP-023, is being investigated in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma.

A phase 2 trial is evaluating ELI-002 7P, a novel cancer vaccine, for the treatment of patients with KRAS-mutant pancreatic cancer.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas.

A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

A phase 1 clinical trial just launched and will test the novel agent, CLN-978, for relapsed/refractory B-cell non-Hodgkin lymphoma.

An ongoing phase 1 trial is analyzing the use of a novel cancer vaccine plus the immunotherapy agent, Keytruda, for patients with triple-negative breast cancer.

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.

A patient with glioblastoma, a type of brain cancer, was dosed with a novel combination immunotherapy as part of a phase 2b trial.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

The TILVANCE-301trial, expected to be completed in 2030, is the latest study of what has been described as one of the “phenomenal discoveries in melanoma.”

This summer, a trial will kick off studying ISM3091 in patients with advanced solid tumors.

Work is underway in the global phase 3 HARMONi study evaluating the combination of ivonescimab and chemotherapy in the treatment of patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer.

The phase 3 HARMONi trial recently kicked off, studying ivonescimab plus chemotherapy for EGFR-mutant non-small cell lung cancer.

A clinical trial studying an accelerated dose of Besremi recently kicked off.

A clinical trial is underway for STX-478, a potential new treatment for breast cancer and other tumors, with initial results expected later this year.

OKN-007 is being evaluated both alone and in combination with chemotherapy for patients with glioma or glioblastoma — both types of brain cancer.

The phase 3 Pragmatica-Lung study evaluating Cyramza and Keytruda has broader eligibility criteria than many other trials, expanding access to more patients and clinicians.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

A pharmaceutical company initiated a phase 1b study in patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.